We are live on ! Find out more

BIOA

BioAge Labs

BIOA

Market cap $390M

8.49 USD

-0.16

1.85%

At close Updated Sep 11, 4:00 PM EDT

Pre-market

After hours

8.49

0.00

0%

1 day

-1.85%

5 days

-9.58%

1 month

-20.43%

3 months

-48.39%

6 months

-57.7%

Year to date

-33.83%

1 year

72.91%

5 years

-53.63%

10 years

-53.63%

About: Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The company's technology platform and differentiated human datasets enable the identification of targets based on insights into molecular changes that drive aging. The Company operates and manages its business as one reportable and operating segment, which is the business of extending healthy human life by targeting molecular causes of aging.

Employees: 62

Healthcare Drug Manufacturers - Specialty & Generic

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 12.5%

Neutral 75%

Negative 12.5%

BioAge Labs, Inc. (BIOA) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

BioAge Labs, Inc. (BIOA) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

BioAge Labs, Inc. (BIOA) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

BioAge Labs Announces First Participant Dosed in QUELL-DME, a Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Diabetic Macular Edema

Randomized, controlled, approximately 180-participant trial evaluates oral BGE-102 as monotherapy and in combination with anti-VEGF therapy Primary endpoint is change in best-corrected visual acuity at week 12 Topline results expected in the second half of 2027 Beyond DME, results will inform development strategy in other NLRP3-driven retinal diseases, including geographic atrophy EMERYVILLE, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (Nasdaq: BIOA) (“BioAge” or the “Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for cardiometabolic diseases by targeting the biology of human aging, today announced that the first participant has been dosed in QUELL-DME, a randomized, controlled Phase 2 trial evaluating once-daily oral BGE-102 in adults with diabetic macular edema (DME).

BioAge Labs Announces First Participant Dosed in QUELL-DME, a Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Diabetic Macular Edema

BioAge: CV Risk Data Due H2 A Major Catalyst After Rival's Data Causes Sell-Off

BioAge Labs remains a buy despite a >40% stock drop, as the recent sell-off appears overblown given competitive Phase 1 data for BGE-102. BGE-102, a best-in-class NLRP3 inhibitor, achieved up to 98% IL-1β suppression and 86% median hsCRP reduction, with Phase 2 topline data expected in H2 2026. BIOA's diversified pipeline includes ophthalmology and apelin-APJ pathway programs, plus partnerships with Novartis and Eli Lilly, supporting long-term optionality.

BioAge: CV Risk Data Due H2 A Major Catalyst After Rival's Data Causes Sell-Off

BioAge Labs to Present at Upcoming Investor Conferences

EMERYVILLE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for cardiometabolic diseases by targeting the biology of human aging, today announced that the Company will participate in the following upcoming investor conferences:

BioAge Labs to Present at Upcoming Investor Conferences

Zacks Investment Research

BioAge Labs, Inc. (BIOA) Reports Q2 Loss, Beats Revenue Estimates

BioAge Labs, Inc. (BIOA) came out with a quarterly loss of $0.58 per share versus the Zacks Consensus Estimate of a loss of $0.65. This compares to a loss of $0.6 per share a year ago.

BioAge Labs, Inc. (BIOA) Reports Q2 Loss, Beats Revenue Estimates

BioAge Labs Reports Second Quarter 2026 Financial Results and Provides Business Updates

First participant dosed in QUELL-CV, a Phase 2 dose-ranging proof-of-concept trial of BGE-102 measuring inflammatory and cardiometabolic biomarkers; topline data anticipated in the second half of 2026

BioAge Labs Reports Second Quarter 2026 Financial Results and Provides Business Updates

Why Is BioAge Labs Stock Sinking Friday?

BioAge Labs Inc. (NASDAQ:BIOA) stock plunged Friday after disappointing Phase 3 cardiovascular trial results from Novo Nordisk A/S (NYSE:NVO) sparked concerns about the potential of NLRP3-targeting therapies.

Why Is BioAge Labs Stock Sinking Friday?

BioAge Labs Announces First Participant Dosed in QUELL-CV, a Phase 2 Proof-of-Concept Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Patients at Elevated Cardiovascular Risk

Randomized, double-blind, placebo-controlled, dose-ranging trial evaluating three once-daily oral doses of BGE-102 in participants with elevated systemic inflammation and additional cardiovascular risk factors

BioAge Labs Announces First Participant Dosed in QUELL-CV, a Phase 2 Proof-of-Concept Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Patients at Elevated Cardiovascular Risk

BioAge Labs, Inc. (BIOA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

BioAge Labs, Inc. (BIOA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

BioAge Labs, Inc. (BIOA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

BioAge Labs Eyes Key BGE-102 Readouts in Heart Risk and Diabetic Eye Disease

BioAge Labs NASDAQ: BIOA executives used a fireside chat at the Jefferies 2026 Global Healthcare Conference to outline the company's plans for BGE-102, its lead NLRP3 inhibitor, with near-term readouts expected in cardiovascular risk and diabetic macular edema.

BioAge Labs Eyes Key BGE-102 Readouts in Heart Risk and Diabetic Eye Disease

See News Rankings

Price charts implemented using Lightweight Charts™